Abstract
Hipericum perforatum is a well-known herbal for its antidepressant property. Recently, it has been shown to have nootropic effects against neurodegenerative disorders. The aim of the present study was to evaluate the protective role of chronic administration of two standardized extract of Hypericum perforatum SHP1 rich in hyperforin (6 %) and SHP2 extract poor in hyperforin (0.2 %) on the neurodegeneration induced by chronic administration of rotenone in rats. Quercetin in liposomes, one active constituent, was tested in the same experimental conditions. The animals received pretreatments with SHP1 (4 mg/Kg, ip), SHP2 (4 mg/Kg, ip) or quercetin liposomes (25 and 100 mg/kg, ip) 60 min before of rotenone injection (2.5 mg/kg) for 45 days. Pretreatment of the animals with SHP1 and SHP2 efficiently halted deleterious toxic effects of rotenone, revealing normalization of catalepsy in addition to amelioration of neurochemical parameters. Also, SHP1 reduced neuronal damage, diminishing substantia nigra dopaminergic cell death caused by the pesticide, indicating benefit of neuroprotective therapy. In general, the SHP1 was more active than SHP2. In addition, SHP1 inhibited the apoptotic cascade by decreasing Bax levels. The results presented here indicate that mainly hyperforin and quercetin, may be involved in the neuroprotective action of Hypericum standardized extracts. Combination of dietary antioxidants could provide better therapeutic advantage for the management of Parkinson, and possibly other neurodegenerative disorders. Therefore H. perforatum standardized extract enriched in hyperforin, could be a better alternative for depressed elderly patients with degenerative disorders exhibiting elevated oxidative stress status.
Keywords: Rotenone, Hypericum perforatum, Parkinson disease, neuroprotective effects.
CNS & Neurological Disorders - Drug Targets
Title:Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson’s Disease
Volume: 12 Issue: 5
Author(s): M.A. Gomez del Rio, M.I. Sanchez-Reus, I. Iglesias, M.A. Pozo, M. Garcia-Arencibia, J. Fernandez-Ruiz, L. García-Garcia, M. Delgado and J. Benedi
Affiliation:
Keywords: Rotenone, Hypericum perforatum, Parkinson disease, neuroprotective effects.
Abstract: Hipericum perforatum is a well-known herbal for its antidepressant property. Recently, it has been shown to have nootropic effects against neurodegenerative disorders. The aim of the present study was to evaluate the protective role of chronic administration of two standardized extract of Hypericum perforatum SHP1 rich in hyperforin (6 %) and SHP2 extract poor in hyperforin (0.2 %) on the neurodegeneration induced by chronic administration of rotenone in rats. Quercetin in liposomes, one active constituent, was tested in the same experimental conditions. The animals received pretreatments with SHP1 (4 mg/Kg, ip), SHP2 (4 mg/Kg, ip) or quercetin liposomes (25 and 100 mg/kg, ip) 60 min before of rotenone injection (2.5 mg/kg) for 45 days. Pretreatment of the animals with SHP1 and SHP2 efficiently halted deleterious toxic effects of rotenone, revealing normalization of catalepsy in addition to amelioration of neurochemical parameters. Also, SHP1 reduced neuronal damage, diminishing substantia nigra dopaminergic cell death caused by the pesticide, indicating benefit of neuroprotective therapy. In general, the SHP1 was more active than SHP2. In addition, SHP1 inhibited the apoptotic cascade by decreasing Bax levels. The results presented here indicate that mainly hyperforin and quercetin, may be involved in the neuroprotective action of Hypericum standardized extracts. Combination of dietary antioxidants could provide better therapeutic advantage for the management of Parkinson, and possibly other neurodegenerative disorders. Therefore H. perforatum standardized extract enriched in hyperforin, could be a better alternative for depressed elderly patients with degenerative disorders exhibiting elevated oxidative stress status.
Export Options
About this article
Cite this article as:
del Rio Gomez M.A., Sanchez-Reus M.I., Iglesias I., Pozo M.A., Garcia-Arencibia M., Fernandez-Ruiz J., García-Garcia L., Delgado M. and Benedi J., Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson’s Disease, CNS & Neurological Disorders - Drug Targets 2013; 12 (5) . https://dx.doi.org/10.2174/1871527311312050013
DOI https://dx.doi.org/10.2174/1871527311312050013 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Pharmacophore, Similarity and ADMET Screening of Casein Kinase 1 inhibitors in Alzheimer's Disease
Current Bioactive Compounds Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States
Current Molecular Medicine Cross-Seeding Interaction Between Amyloid β and Tau Protein can Enhance Aggregation
Current Biotechnology Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Oxidative Stress in Traumatic Brain Injury
Current Medicinal Chemistry New Insights into Endocannabinoid Degradation and its Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Mitochondria, Mitochondrial DNA and Alzheimers Disease. What Comes First?
Current Alzheimer Research Melatonin Synthetic Analogs as Nitric Oxide Synthase Inhibitors
Mini-Reviews in Medicinal Chemistry Curcumin Exposure Modulates Multiple Pro-Apoptotic and Anti-Apoptotic Signaling Pathways to Antagonize Acetaminophen-Induced Toxicity
Current Neurovascular Research Targeting Conserved Pathways: Mitochondrial Dysfunction and Beyond
Current Neurovascular Research Editors Note
Current Molecular Medicine Colon Targeted Rifaximin Nanosuspension for the Treatment of Inflammatory Bowel Disease (IBD)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry De Novo and Molecular Target-Independent Discovery of Orally Bioavailable Lead Compounds for Neurological Disorders
Current Alzheimer Research Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?
Current Alzheimer Research Aptamers as Innovative Diagnostic and Therapeutic Agents in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Sirtuins as Possible Targets in Neurodegenerative Diseases
Current Drug Targets Editorial (Thematic Issue: NAD<sup>+</sup> Biosynthesis and Signaling as an Emerging Area in Medicinal Chemistry)
Current Topics in Medicinal Chemistry Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design